This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||
|
Untitled
editThis sentence is not right. can someone restructure it? possibly to lead to a latter fleshing out of each aspect.
>This explains why many childhood diseases never recur in adulthood (and >if they do, it generally indicates immunosuppression) or failure of a >vaccine.
Wiki Education Foundation-supported course assignment
editThis article was the subject of a Wiki Education Foundation-supported course assignment, between 26 October 2021 and 19 November 2021. Further details are available on the course page. Student editor(s): Oddvector. Peer reviewers: HeidiCarpenter23.
Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 09:00, 17 January 2022 (UTC)
FDA defines Seroconversion in influenza vaccine 4-fold jump in HI antibody. What do EU & WHO require?
editSeroconversion is defined as an increase in HI (Hemagglutination-Inhibition) antibody titer of at least 4-fold, with a minimum post-vaccination HI titer of 1:40.
I believe this refers to results from a Viral Hemagglutination Assay
I believe a 60% seroconversion rate among immunonaieve patients is one of the standards for licensure of a vaccine by the FDA.
– Seroconversion – defined as % subjects with a minimum 4-fold rise in HI titer (e.g., pre-vaccination HI titer < 1:10 and a post vaccination titer > 1:40, or a pre-vaccination titer > 1:10 and a minimum 4-fold rise HI titer) – Seroprotection – defined as % subjects with an HI titer > 1:40
FDA also requires – a specified increase in HI antibody Geometric Mean Titer (GMT) following vaccination.
— Preceding unsigned comment added by Ocdncntx (talk • contribs) 02:40, 27 February 2011 (UTC)
seroconversion per wiktionary 2011 Feb 27
editseroconversion (plural seroconversions)
Noun
(immunology) The development of specific antibodies in the blood serum as a result of infection or immunization
Expanding seroconversion
editHi everyone, I'll be tweaking and expanding on this page and plan to work on the following:
- adding citations and sources throughout the page, especially for the mechanism section
- re-organising the terminology section for better flow and removing the bolding of terms, which does not seem to fit the style guidelines as far as I can tell
- rewriting the mechanism and background section to add more information that should help make it more understandable and less reliant on medical jargon, as well as expanding those sections to give more information
- adding specific sections on seroconversion in:
- HIV/AIDS (including symptoms of the seroconversion period, how testing works, and clinical relevance of seroconversion testing for diseases such as Kaposi sarcoma);
- COVID-19 (including how seroconversion differs for different populations and how this suggests different disease courses);
- the role and relevance of seroconversion to vaccination
If anyone has any suggestions, especially for secondary/tertiary sources, I would be grateful! I have mostly been able to find primary sources on many of these topics.
For sources, I have located the following thus far and will continue to look more secondary/tertiary sources, with efforts to not use some of the primary sources I have found. Oddvector (talk) 06:17, 2 November 2021 (UTC)
WikiMed Assignment: Review of work
editLead section: The lead section is well written and easy to follow. It defines seroconversion and starts the conversation about the response to antigen and antibody formation. It also touches on the importance of the tests used to detect antibodies. Overall, the only critique I have is that it is written at a high-grade level with complex sentences and vocabulary. For this topic, that might not be a huge deal since it’s pretty niche, but something to consider.
Organization: I think the sections of Mechanism, Terminologies and specific discussion on HIV, COVID-19 and Hepatitis B are excellent. I like that you did specific sections for each disease pattern since their seroconversion mechanism and timelines are different. I also like that you included the mechanism and terminologies discussions ahead of the disease-specific discussion because it allows a groundwork for more advanced concepts.
Your sources are excellent and from reputable places with neutral content throughout. This is especially important in the HIV section, where there is often a considerable social stigma around HIV infection.
Overall, I was very impressed with how much you added to this article! It started very bare and has really grown with your effort. I loved the attention to detail you provided in all the sections, down to the specific antibodies formed. This would be especially helpful for folks who are new to understanding antibodies and how they are very specific. It would be very helpful for someone who was recently seroconverted for one of these diseases.
In terms of completeness, I was really impressed! You go into excellent detail about vaccines, testing, and symptom onset for each condition with varying antibody titers. You even talk about PrEP, false positives in the assays, seroreversion and some epidemiologic concepts.
My only thoughts are maybe shortening some sentences and maybe using less complex vocabulary in places for folks who may have less STEM background.
Error?
edit> Thus, tests at this stage are unable to detect sufficient unbound antigen.
Should this say antibody as the context here is antigen dominant.
Raisins31415 (talk) 04:59, 5 March 2024 (UTC)